Spdr Sp Pharmaceuticals Etf Profile

XPH Etf  USD 40.63  0.41  1.00%   

Performance

Very Weak

 
Weak
 
Strong

Odds Of Distress

Below Average

 
High
 
Low
SPDR SP is trading at 40.63 as of the 30th of June 2025. This is a 1 percent decrease since the beginning of the trading day. The etf's open price was 41.04. SPDR SP has about a 38 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 1st of April 2025 and ending today, the 30th of June 2025. Click here to learn more.
In seeking to track the performance of the SP Pharmaceuticals Select Industry Index , the fund employs a sampling strategy. SP Pharmaceuticals is traded on NYSEARCA Exchange in the United States. More on SPDR SP Pharmaceuticals

Moving together with SPDR Etf

  0.68IBB iShares Biotechnology ETFPairCorr
  0.77XBI SPDR SP Biotech Sell-off TrendPairCorr
  0.77IHI iShares Medical DevicesPairCorr
  0.61IXJ iShares Global HealthcarePairCorr

Moving against SPDR Etf

  0.84VXX iPath Series BPairCorr
  0.84VIXY ProShares VIX ShortPairCorr
  0.5IHF iShares HealthcarePairCorr
  0.35YCL ProShares Ultra YenPairCorr

SPDR Etf Highlights

Vice PresidentMichael Riley
Thematic Ideas
(View all Themes)
Old NameHanoi Soap JSC
Business ConcentrationHealth Care ETFs, Sector ETFs, Health, SPDR State Street Global Advisors (View all Sectors)
IssuerSSgA
Inception Date2006-06-19
BenchmarkS&P Pharmaceuticals Select Industry Index
Entity TypeRegulated Investment Company
Asset Under Management149.79 Million
Average Trading Valume41,328.6
Asset TypeEquity
CategorySector
FocusHealth Care
Market ConcentrationDeveloped Markets
RegionNorth America
AdministratorSSgA Funds Management, Inc.
AdvisorSSgA Funds Management, Inc.
CustodianState Street Bank and Trust Company
DistributorState Street Global Advisors Funds Distributors, LLC
Portfolio ManagerMichael Feehily, Karl Schneider, Keith Richardson
Transfer AgentState Street Bank and Trust Company
Fiscal Year End30-Jun
ExchangeNYSE Arca, Inc.
Number of Constituents57.0
Market MakerCitadel
Total Expense0.35
Management Fee0.35
Country NameUSA
Returns Y T D(4.94)
NameSPDR SP Pharmaceuticals ETF
Currency CodeUSD
Open FigiBBG000D73SW9
In Threey Volatility17.62
1y Volatility15.0
200 Day M A43.3536
50 Day M A40.4624
CodeXPH
Updated At29th of June 2025
Currency NameUS Dollar
SPDR SP Pharmaceuticals [XPH] is traded in USA and was established 2006-06-19. The fund is classified under Health category within SPDR State Street Global Advisors family. The entity is thematically classified as Health Care ETFs. SPDR SP Pharmaceuticals at this time have 206.63 M in net assets. , while the total return for the last 3 years was -0.8%.
Check SPDR SP Probability Of Bankruptcy

Geographic Allocation (%)

Top SPDR SP Pharmaceuticals Etf Constituents

MRKMerck CompanyStockHealth Care
ZTSZoetis IncStockHealth Care
VTRSViatrisStockHealth Care
SAVACassava SciencesStockHealth Care
RPRXRoyalty Pharma PlcStockHealth Care
PRGOPerrigo Company PLCStockHealth Care
PFEPfizer IncStockHealth Care
PCRXPacira BioSciences,StockHealth Care
More Details

SPDR SP Top Holders

PILLDirexion Daily PharmaceuticalEtfTrading--Leveraged Equity
CAPTXCanterbury Portfolio ThermostatMutual FundTactical Allocation
LCAIXLazard Capital AllocatorMutual FundTactical Allocation
LCAOXLazard Capital AllocatorMutual FundTactical Allocation
More Details

SPDR SP Pharmaceuticals Risk Profiles

The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in SPDR SP. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures.

SPDR SP Against Markets

When determining whether SPDR SP Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of SPDR SP's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Spdr Sp Pharmaceuticals Etf. Outlined below are crucial reports that will aid in making a well-informed decision on Spdr Sp Pharmaceuticals Etf:
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in SPDR SP Pharmaceuticals. Also, note that the market value of any etf could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
The market value of SPDR SP Pharmaceuticals is measured differently than its book value, which is the value of SPDR that is recorded on the company's balance sheet. Investors also form their own opinion of SPDR SP's value that differs from its market value or its book value, called intrinsic value, which is SPDR SP's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because SPDR SP's market value can be influenced by many factors that don't directly affect SPDR SP's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between SPDR SP's value and its price as these two are different measures arrived at by different means. Investors typically determine if SPDR SP is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, SPDR SP's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.